In 2024, the National Youth Tobacco Survey revealed a significant decrease in e-cigarette use among U.S. middle and high school students, with current use dropping from 2.13 million (7.7%) in 2023 to 1.63 million (5.9%) in 2024.

On June 5, 2024, the Vaccines and Related Biological Products Advisory Committee (VRBAC) and FDA panel met and unanimously voted for the JN.1 strain for the new fall 2024-25 COVID-19 vaccine formulation. A week later, based on updated data, the FDA asked the vaccine manufacturers to focus on the KP.2 and KP.3 strains of the JN.1 lineage as they are becoming the more dominant strains. It is anticipated that the change requested by the FDA will not cause any delays in the manufacturing of the new formulations.

As temperatures rise and weather conditions become more unpredictable, SpecialtyRx takes proactive steps to ensure the safety, efficacy, and availability of medications across all of our facilities — especially in regions where heat and extreme weather are seasonal challenges.